Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
62 hedge funds and large institutions have $259M invested in Paratek Pharmaceuticals, Inc. in 2015 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 21 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
3% more funds holding
Funds holding: 60 → 62 (+2)
2% less capital invested
Capital invested by funds: $264M → $259M (-$4.76M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
29% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.4M |
| 2 |
OPPM
Opus Point Partners Management
New York
|
+$1.15M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$588K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$323K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$303K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$5.76M |
| 2 |
Bank of New York Mellon
New York
|
-$3.61M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.88M |
| 4 |
OA
Omega Advisors
New York
|
-$449K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$409K |
PRTK Hedge Fund Activity: Q4 2015 in Review
62 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q4 2015, worth a combined $259M — down 1.8% from $264M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new PRTK positions and 4 closed out — a net gain of 2 holders — while 15 added to existing stakes and 21 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $4.4M. The largest seller was Jennison Associates, exiting entirely with an estimated $5.76M sold.
- 62 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q4 2015, up from 60 in Q3 2015.
- Funds reported $259M of Paratek Pharmaceuticals, Inc. stock for Q4 2015, down 1.8% quarter-over-quarter.
- 6 funds opened new Paratek Pharmaceuticals, Inc. positions in Q4 2015 and 4 closed out, a net change of +2 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q4 2015 was Fidelity Investments, an estimated $4.4M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q4 2015 was Jennison Associates, an estimated $5.76M sold.
Based on aggregated 13F filings for Q4 2015.